The historical rank and industry rank for Chordate Medical Holding AB's Net Margin % or its related term are showing as below:
OSTO:CMH'
s Net Margin % Range Over the Past 10 Years
Min: -25635.78 Med: -2907.2 Max: -2138.23
Current: -2533.74
OSTO:CMH's Net Margin % is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 2.09
vs OSTO:CMH: -2533.74
Chordate Medical Holding AB (OSTO:CMH) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Chordate Medical Holding AB Net Margin % Related Terms
Chordate Medical Holding AB Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:CMH vs ABT, SYK, MDT: Net Margin % Comparison
For the Medical Devices subindustry, Chordate Medical Holding AB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chordate Medical Holding AB Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Chordate Medical Holding AB's Net Margin % distribution charts can be found below:
* The bar in red indicates where Chordate Medical Holding AB's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chordate Medical Holding AB (OSTO:CMH) has a Net Margin % of -3,185.28% as of Jun. 2025. Net margin is the ratio of total net income to net sales. View historical data on Chordate Medical Holding AB and its competitors.
Is Chordate Medical Holding AB's Net Margin % too high?
Chordate Medical Holding AB's current Net Margin % is -3,185.28%. Overall, Chordate Medical Holding AB has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Chordate Medical Holding AB's Net Margin % compare to ABT and SYK?
Chordate Medical Holding AB's Net Margin % of -3,185.28% can be compared against companies in the Medical Devices & Instruments industry. The industry median Net Margin % is 2.09. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.09, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Chordate Medical Holding AB and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chordate Medical Holding AB's current Net Margin % is -3,185.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chordate Medical Holding AB stock overvalued right now?
Chordate Medical Holding AB (OSTO:CMH) has a current Net Margin % of -3,185.28%. The stock's GF Value™ is kr26.18, compared to a current price of kr0.16 — trading 99.4% below its estimated fair value. The current Net Margin % is -3,185.28%. Chordate Medical Holding AB's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Chordate Medical Holding AB (OSTO:CMH), the current Net Margin % is -3,185.28% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chordate Medical Holding AB (OSTO:CMH) Overvalued in 2026?
Based on GuruFocus' analysis, Chordate Medical Holding AB stock appears to be undervalued.
The current stock price of kr0.16 is trading 99.4% below its estimated GF Value™ of kr26.18.
Key valuation signals for OSTO:CMH:
Net Margin %: -3,185.28%
GF Value™: kr26.18 vs. price of kr0.16 (99.4% below fair value)
No single metric tells the full story. See the OSTO:CMH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chordate Medical Holding AB is a medical technology company that has developed patented and CE-marked a new nerve-modulating treatment technology for chronic nasal congestion and chronic migraine. The company sells its products in Selected European markets, Israel, and Saudi Arabia. The company's product range is based on the CE-marked treatment units Chordate System S100 and S120 for rhinitis and S220 for migraine, registered for the indications of preventive treatment of chronic migraine and chronic rhinitis and use on patients. The company sells its product system, including treatments, through distributors to clinics and hospitals in its primary markets.
46GF Score
Get the complete analysis for OSTO:CMH
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:CMH has been successfully added to your 
